Brain and acute leukemia, cytoplasmic overexpression as a prognostic factor in egyptian De novo adult acute myeloid leukemia patients

Background: Brain and acute leukemia, cytoplasmic (BAALC) gene is identified on chromosome 8q22.3 and implicated in normal hematopoiesis. BAALC gene overexpression is associated with poor outcome. Methods: We aimed to evaluate BAALC expression in de novo Egyptian acute myeloid leukemia (AML) cases a...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of medical and paediatric oncology Vol. 41; no. 6; pp. 859 - 868
Main Authors Alnagar, Ahmed, Hagrassy, Hesham Al, Abdullah, Rania, Shabrawy, Reham El, Salah, Hossam
Format Journal Article
LanguageEnglish
Published New Delhi Medknow Publications and Media Pvt. Ltd 01.11.2020
Medknow Publications & Media Pvt. Ltd
Subjects
Ethylenediaminetetraacetic acid
Genes
Genetic aspects
Induction therapy
Leukemia
Egypt
Online AccessGet full text

Cover

More Information
Summary:Background: Brain and acute leukemia, cytoplasmic (BAALC) gene is identified on chromosome 8q22.3 and implicated in normal hematopoiesis. BAALC gene overexpression is associated with poor outcome. Methods: We aimed to evaluate BAALC expression in de novo Egyptian acute myeloid leukemia (AML) cases and determine its prognostic value. We recruited 70 patients with de novo AML diagnosed and treated at clinical pathology and medical oncology departments, fulfilling inclusion criteria in our prospective study and evaluated BAALC expression level. Patients received induction therapy. The Institutional Review Board approved our study. Results: The mean age was 39.2 years ± 11.87, (18–60) with a male/female ratio of 3/2. The cutoff value of BAALC as a prognostic factor was 2.11 with sensitivity (86.1%), specificity (80%), positive predictive value (88.6%), and negative predictive value (76.2%.) (P < 0.001), 43 (61.4%) patients had high BAALC expression. Seventy-two percent of patients in the low BAALC group achieved complete remission (CR) compared to 42.1% in high BAALC expression group (P = 0.03). Patients with low BAALC (123.1 ± 4.9) had longer mean survival time than high BAALC group (45.85 ± 5.1) (P = 0.000). Conclusion: High-BAALC expression is an adverse prognostic factor, with a higher risk of relapse, lower CR rates, and lower survival in Egyptian de novo AML patients.
ISSN:0971-5851
0975-2129
DOI:10.4103/ijmpo.ijmpo_215_20